重度の慢性心不全患者のカルベディロール投与開始の効果:コペルニクス研究の結果
Henry Krum1, Ellen B Roecker, Paul Mohacsi
1Dept of Medicine and Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, 3181 Australia. henry.krum@med.monash.edu.au
JAMA
|February 15, 2003
まとめ
重度の心不全患者のカルベディロールの早期使用は,リスクの増加なしに利益を示しました. このベータブロッカーは数週間で肯定的な結果を示し,心不全管理のためのより広範な採用を奨励しました.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- ベータブロッカーは心不全 (HF) の管理に不可欠ですが,未充分に利用されています.
- 遅れた利益と潜在的なリスクに関する懸念は,HF患者のベータブロッカーの開始を阻害する可能性があります.
研究 の 目的:
- 重度の心不全患者のカルベディロールの早期治療効果と安全性プロフィールを評価する.
主な方法:
- ランダム化,ダブルブラインド,プラセボ対照試験で,重度の心不全の患者2289人が参加しました.
- 患者は,カルベディロールまたはプラセボを標準的なHF薬と併用して投与された.
- 測定されたアウトカムには,最初の8週間以内に死亡,入院,および有害事象が含まれていました.
主要な成果:
- カーベディロールは,心血管疾患のリスクを増加させなかったが,むしろ,死亡者数と入院者数の減少という傾向を示した.
- 治療開始後14~21日以内に効果が認められた.
- 心不全の悪化は,カルベディロール群とプラセボ群の両方で同様の頻度で発生しました.
結論:
- 臨床的に安定した重症心不全患者のカルベディロールの投与を開始すると,長期的な治療に匹敵する利点が得られます.
- 早期のリスク・ベネフィットプロファイルは,心不全管理におけるカルベディロールの使用の増加を支持しています.
関連する概念動画
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...